6ANA
 
 | | LL2 Fab in complex with anti-Kappa VHH domain | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, LL2 Fab Heavy Chain, LL2 Fab Light Chain, ... | | Authors: | Sicard, T, Ereno Orbea, J, Julien, J.-P. | | Deposit date: | 2017-08-12 | | Release date: | 2018-01-31 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (1.7 Å) | | Cite: | Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments.
J. Mol. Biol., 430, 2018
|
|
5VKK
 | |
5VL3
 | | CD22 d1-d3 in complex with therapeutic Fab Epratuzumab | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, B-cell receptor CD22, Epratuzumab Fab Heavy Chain, ... | | Authors: | Sicard, T, Ereno-Orbea, J, Julien, J.P. | | Deposit date: | 2017-04-24 | | Release date: | 2017-10-11 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (3.1 Å) | | Cite: | Molecular basis of human CD22 function and therapeutic targeting.
Nat Commun, 8, 2017
|
|
6X4T
 | | Crystal structure of ICOS-L in complex with Prezalumab and VNAR domain | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, ... | | Authors: | Rujas, E, Sicard, T, Julien, J.P. | | Deposit date: | 2020-05-23 | | Release date: | 2020-10-14 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (3.15 Å) | | Cite: | Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
Nat Commun, 11, 2020
|
|
6X4G
 | | Crystal structure of ICOS in complex with ICOS-L and an anti ICOS-L VNAR domain | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, ICOS ligand, ... | | Authors: | Rujas, E, Sicard, T, Julien, J.P. | | Deposit date: | 2020-05-22 | | Release date: | 2020-10-14 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (3.5 Å) | | Cite: | Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
Nat Commun, 11, 2020
|
|
7O52
 | | CD22 d6-d7 in complex with Fab m971 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CD22 d6-d7 Ig domains, GLYCEROL, ... | | Authors: | Ereno-Orbea, J, Sicard, T, Julien, J.P. | | Deposit date: | 2021-04-07 | | Release date: | 2021-07-28 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.41 Å) | | Cite: | Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22.
J.Biol.Chem., 297, 2021
|
|
7O4Y
 | |
7JOO
 | | Crystal structure of ICOS in complex with antibody STIM003 and anti-kappa VHH domain | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, Inducible T-cell costimulator, ... | | Authors: | Rujas, E, Sicard, T, Julien, J.P. | | Deposit date: | 2020-08-06 | | Release date: | 2020-10-14 | | Last modified: | 2023-10-25 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
Nat Commun, 11, 2020
|
|
6AND
 | | Pinatuzumab Fab in complex with anti-Kappa VHH domain | | Descriptor: | Anti-kappa VHH domain, GLYCEROL, Pinatuzumab Fab Heavy chain, ... | | Authors: | Ereno-Orbea, J, Sicard, T, Julien, J.-P. | | Deposit date: | 2017-08-12 | | Release date: | 2018-01-31 | | Last modified: | 2019-05-08 | | Method: | X-RAY DIFFRACTION (1.75 Å) | | Cite: | Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments.
J. Mol. Biol., 430, 2018
|
|
6ANI
 | | Coltuximab Fab in complex with anti-Kappa VHH domain | | Descriptor: | Anti-Kappa VHH domain, Coltuximab Fab heavy chain, Coltuximab Fab light chain, ... | | Authors: | Ereno Orbea, J, Sicard, T, Julien, J.-P. | | Deposit date: | 2017-08-13 | | Release date: | 2018-01-31 | | Last modified: | 2019-10-16 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Structural Basis of Enhanced Crystallizability Induced by a Molecular Chaperone for Antibody Antigen-Binding Fragments.
J. Mol. Biol., 430, 2018
|
|
5VKM
 | | Crystal structure of human CD22 Ig domains 1-3 in complex with alpha 2-6 sialyllactose | | Descriptor: | B-cell receptor CD22, GLYCEROL, N-acetyl-alpha-neuraminic acid-(2-6)-beta-D-galactopyranose, ... | | Authors: | Julien, J.P, Ereno-Orbea, J, Sicard, T. | | Deposit date: | 2017-04-21 | | Release date: | 2017-10-04 | | Last modified: | 2023-10-04 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Molecular basis of human CD22 function and therapeutic targeting.
Nat Commun, 8, 2017
|
|
5VKJ
 | | Crystal structure of human CD22 Ig domains 1-3 | | Descriptor: | B-cell receptor CD22, GLYCEROL, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose | | Authors: | Julien, J.P, Ereno-Orbea, J, Sicard, T. | | Deposit date: | 2017-04-21 | | Release date: | 2017-10-04 | | Last modified: | 2024-04-03 | | Method: | X-RAY DIFFRACTION (2.12 Å) | | Cite: | Molecular basis of human CD22 function and therapeutic targeting.
Nat Commun, 8, 2017
|
|
